Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

Journal:

Nature Medicine

Published:

2025-05-16

DOI:

10.1038/s41591-025-03658-y

Affiliations:

21

Authors:

28

Go to article

Institutions	Authors	Share
Roche R&D Center (China) Ltd., China	7.000000	0.25
Genentech, Inc., United States of America (USA)	3.000000	0.11
Wuhan Union Hospital, HUST, China	1.000000	0.04
Harbin Medical University Cancer Hospital, China	1.000000	0.04
Shandong Cancer Hospital, China	1.000000	0.04
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.04
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.04
Hangzhou Institute of Medicine (HIM), CAS, China	1.000000	0.04
Jilin Province Cancer Hospital, China	1.000000	0.04
Sir Run Run Shaw Hospital (SRRSH), Zhejiang University School of Medicine, China	1.000000	0.04
Nantong Tumor Hospital, China	1.000000	0.04
The First Hospital of Jilin University, China	1.000000	0.04
Drum Tower Hospital, China	1.000000	0.04
PLA No. 900 Hospital of the Joint Support Force (PLA No. 900 Hospital), China	1.000000	0.04
Liaoning Cancer Hospital and Institute, China	1.000000	0.04
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.04
Henan Cancer Hospital, ZZU, China	1.000000	0.04
The First Affiliated Hospital, GMU, China	1.000000	0.04
Peking Union Medical College Hospital (PUMCH), China	1.000000	0.04
Shanghai East Hospital, Tongji University, China	0.500000	0.02
Shanghai Pulmonary Hospital, China	0.500000	0.02

Interested in Oncology and Carcinogenesis?